Derbend Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Derbend Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,171	Closed	-$210K	–	97
2023 Q2	$210K	Buy	+6,171	New	+$194K	0.14%	76
2022 Q4	–	Sell	-7,602	Closed	-$250K	–	77
2022 Q3	$250K	Sell	7,602 -280	-4%	-$10.3K	0.2%	67
2022 Q2	$248K	Sell	7,882 -6,482	-45%	-$227K	0.21%	61
2022 Q1	$880K	Hold	14,364	–	–	0.86%	42
2021 Q4	$880K	Sell	14,364 -3,365	-19%	-$233K	0.86%	42
2021 Q3	$1.32M	Sell	17,729 -551	-3%	-$46.2K	1.24%	22
2021 Q2	$1.69M	Buy	+18,280	New	+$1.55M	1.58%	16

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

Derbend Asset Management's ARKG Position: Q3 2023 in Review

Derbend Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2023, closing a stake of 6,171 shares — an estimated $210K sold.

Derbend Asset Management first reported a position in ARKG in Q2 2021 and held it in 7 quarters. The position peaked at $1.69M in Q2 2021. 286 funds tracked by Wall St. Rank hold ARKG as of Q3 2023.

Derbend Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q3 2023 after selling out during the quarter.
Derbend Asset Management sold 6,171 ARK Genomic Revolution ETF shares in Q3 2023, an estimated $210K.
Derbend Asset Management first reported a position in ARK Genomic Revolution ETF in Q2 2021 and held it in 7 quarters.
Derbend Asset Management's ARK Genomic Revolution ETF position peaked at $1.69M in Q2 2021.
286 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2023.

Based on Derbend Asset Management's 13F filing for Q3 2023, filed 19 Oct 2023.